Huons Global Co Ltd

Chart & Performance

D1W1MN

No data to show

P/E

22.04

P/S

0.70

EPS

2,105.72

Div Yield, %

1.19%

Shrs. gr., 5y

0.37%

Rev. gr., 5y

12.60%

Revenues

813.46b

+7.26%

Net income

25.79b

-32.81%

CFO

100.57b

+0.60%

Dividend

Jun 27, 2024275 KRW/sh

Profile

Huons Global Co., Ltd. provides medical solutions for human health in South Korea and internationally. The company offers oral solid form products in the areas of circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, other chemotherapeutic, and others; and injections in the areas of anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic, antihistamine, adrenocortical hormone, enzyme, mineral, solvent, calcium, hemostatic, antidote, antibiotic, metabolic, hyaluronic acid, well-being, anticoagulant, and others, as well as circulatory, respiratory, and other tissue cell systems. It also provides medical devices, eye drop products, and bio products. The company was formerly known as Huons Co., Ltd. and changed its name to Huons Global Co., Ltd. in June 2016. Huons Global Co., Ltd. was founded in 1965 and is headquartered in Seongnam, South Korea.

URL

https://huonsglobal.com/web/home_.php

IPO date

Dec 19, 2006

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	813,460,515 7.26%	758,379,661 14.15%	664,364,718 15.61%
Cost of revenue	639,830,698	572,141,581	512,583,265
Unusual Expense (Income)
NOPBT	173,629,817	186,238,080	151,781,453
NOPBT Margin	21.34%	24.56%	22.85%
Operating Taxes	23,236,314	27,004,572	33,740,386
Tax Rate	13.38%	14.50%	22.23%
NOPAT	150,393,503	159,233,508	118,041,067
Net income	25,791,032 -32.81%	38,383,627 -163.70%	(60,254,135) -1,608.41%
Dividends	(15,596,731)	(19,480,052)	(5,911,198)
Dividend yield	2.96%	6.72%	2.57%
Proceeds from repurchase of equity	(1,999,979)	531,978	15,348,373
BB yield	0.38%	-0.18%	-6.66%
Debt
Debt current	196,923,145	176,776,630	217,080,192
Long-term debt	105,035,673	75,468,172	72,473,267
Deferred revenue	9,458,313	9,676,226	9,021,332
Other long-term liabilities	22,729,321	21,673,029	6,420,509
Net debt	(47,170,477)	(146,369,782)	(201,408,763)
Cash flow
Cash from operating activities	100,571,082	99,967,135	64,373,890
CAPEX	(133,765,981)	(79,774,245)	(78,716,796)
Cash from investing activities	(131,498,752)	(63,464,343)	(1,068,937)
Cash from financing activities	32,314,226	(77,309,350)	1,770,588
FCF	42,331,505	(400,341)	69,452,724
Balance
Cash	278,677,671	312,552,775	367,861,473
Long term investments	70,451,624	86,061,809	123,100,748
Excess cash	308,456,269	360,695,601	457,743,985
Stockholders' equity	615,455,691	552,593,118	435,170,878
Invested Capital	985,283,926	828,192,389	636,339,935
ROIC	16.59%	21.75%	18.74%
ROCE	13.35%	15.60%	14.12%
EV
Common stock shares outstanding	12,189	12,248	12,289
Price	43,250.00 82.88%	23,650.00 26.13%	18,750.00 -51.30%
Market cap	527,185,625 82.00%	289,666,974 25.71%	230,426,438 -51.84%
EV	924,071,455	560,221,600	357,818,194
EBITDA	213,941,145	222,218,303	185,355,033
EV/EBITDA	4.32	2.52	1.93
Interest	10,472,774	7,598,050	12,758,610
Interest/NOPBT	6.03%	4.08%	8.41%